西达基奥仑赛或标准治疗用于来那度胺难治性多发性骨髓瘤
这项3期随机开放标签试验将419例来那度胺难治性多发性骨髓瘤患者(既往1–3线治疗)分配至西达基奥仑赛(cilta-cel)组或医生选择的标准治疗组。中位随访15.9个月时,cilta-cel组中位无进展生存期未达到,标准治疗组为11.8个月(HR 0.26;95%CI 0.18–0.38;P<0.001)。
要点
- cilta-cel组12个月无进展生存率为75.9%,标准治疗组为48.6%。
- cilta-cel组总缓解率84.6%、完全缓解或更好73.1%、微小残留病阴性60.6%,均高于标准治疗组。
- cilta-cel组细胞因子释放综合征发生率76.1%,3或4级1.1%,无5级。
核心结论
- 在既往接受1–3线治疗的来那度胺难治性多发性骨髓瘤患者中,单次cilta-cel输注较标准治疗降低疾病进展或死亡风险。
研究设计与样本
- 3期随机开放标签试验,纳入来那度胺难治性多发性骨髓瘤患者,随机分配至cilta-cel组(208例)或医生选择的标准治疗组(211例),共419例。
- 所有患者既往接受1–3线治疗,主要结局为无进展生存期。
主要发现
- 中位随访15.9个月(范围0.1–27.3)时,cilta-cel组中位无进展生存期未达到,标准治疗组为11.8个月(HR 0.26;95%CI 0.18–0.38;P<0.001)。
- 12个月无进展生存率cilta-cel组为75.9%(95%CI 69.4–81.1),标准治疗组为48.6%(95%CI 41.5–55.3)。
- cilta-cel组总缓解率84.6% vs 标准治疗组67.3%;完全缓解或更好73.1% vs 21.8%;微小残留病阴性60.6% vs 15.6%。
- 全因死亡cilta-cel组39例,标准治疗组46例(HR 0.78;95%CI 0.5–1.2)。
- 接受cilta-cel的176例患者中,细胞因子释放综合征134例(76.1%;3或4级1.1%;无5级),免疫效应细胞相关神经毒性综合征8例(4.5%,均为1或2级),运动和神经认知症状1例(1级),颅神经麻痹16例(9.1%;2级8.0%,3级1.1%),CAR-T相关周围神经病5例(2.8%;1或2级2.3%,3级0.6%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed CAR T-cell therapy, is effective in heavily pretreated patients with relapsed or refractory multiple myeloma. We investigated cilta-cel in earlier treatment lines in patients with lenalidomide-refractory disease. METHODS: In this phase 3, randomized, open-label trial, we assigned patients with lenalidomide-refractory multiple myeloma to receive cilta-cel or the physician's choice of effective standard care. All the patients had received one to three previous lines of treatment. The primary outcome was progression-free survival. RESULTS: A total of 419 patients underwent randomization (208 to receive cilta-cel and 211 to receive standard care). At a median follow-up of 15.9 months (range, 0.1 to 27.3), the median progression-free survival was not reached in the cilta-cel group and was 11.8 months in the standard-care group (hazard ratio, 0.26; 95% confidence interval [CI], 0.18 to 0.38; P<0.001). Progression-free survival at 12 months was 75.9% (95% CI, 69.4 to 81.1) in the cilta-cel group and 48.6% (95% CI, 41.5 to 55.3) in the standard-care group. More patients in the cilta-cel group than in the standard-care group had an overall response (84.6% vs. 67.3%), a complete response or better (73.1% vs. 21.8%), and an absence of minimal residual disease (60.6% vs. 15.6%). Death from any cause was reported in 39 patients and 46 patients, respectively (hazard ratio, 0.78; 95% CI, 0.5 to 1.2). Most patients reported grade 3 or 4 adverse events during treatment. Among the 176 patients who received cilta-cel in the as-treated population, 134 (76.1%) had cytokine release syndrome (grade 3 or 4, 1.1%; no grade 5), 8 (4.5%) had immune effector cell-associated neurotoxicity syndrome (all grade 1 or 2), 1 had movement and neurocognitive symptoms (grade 1), 16 (9.1%) had cranial nerve palsy (grade 2, 8.0%; grade 3, 1.1%), and 5 (2.8%) had CAR-T-related peripheral neuropathy (grade 1 or 2, 2.3%; grade 3, 0.6%). CONCLUSIONS: A single cilta-cel infusion resulted in a lower risk of disease progression or death than standard care in lenalidomide-refractory patients with multiple myeloma who had received one to three previous therapies. (Funded by Janssen and Legend Biotech; CARTITUDE-4 ClinicalTrials.gov number, NCT04181827.).
引用
- San-Miguel J, Dhakal B, Yong K, et al. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. N Engl J Med. 2023. PMID: 37272512. doi:10.1056/NEJMoa2303379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。